Log in

ASX:BCTBluechiip Stock Price, Forecast & News

A$0.07
-0.01 (-12.66 %)
(As of 05/13/2020)
Add
Compare
Today's Range
A$0.07
Now: A$0.07
A$0.08
50-Day Range
A$0.06
MA: A$0.07
A$0.07
52-Week Range
A$0.05
Now: A$0.07
A$0.20
Volume134,495 shs
Average VolumeN/A
Market Capitalization$40.92 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Bluechiip Limited develops and commercializes wireless tracking solutions for the healthcare and life science, security, defense, and manufacturing industries. The company offers Bluechiip products, such as retrofit button for CryoVials; Bluechiip enabled CryoVial boxes to enable ID and temperature recording; CryoTag measure sample temperatures of racks, cassettes, towers, and tanks; Matchbox Reader to read the Bluechiip-enabled vials and CryoTags; and Multi-Vial Reader to scan the ID and temperature of 100 vials in a Bluechiip CryoBox. It also provides Hand-Held Reader to scan Bluechiip-enabled Cryovials; Stream Sample-Management Software, a Web-based sample-management and temperature chain-of-custody application for bio-samples stored in cryogenic environments; Blood Cassettes, which are polycarbonate cassettes to store blood bags with platelet and plasma concentrates; and stainless steel towers/racks/frames to store cryogenic boxes. The company was founded in 2003 and is headquartered in Scoresby, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.66 out of 5 stars


Industry, Sector and Symbol

Industry Semiconductors
Sub-IndustryN/A
SectorComputer and Technology
CUSIPN/A
CIKN/A
Phone61 3 9763 9763

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$941,221.00
Cash FlowA$0.02 per share
Book ValueA$0.02 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$40.92 million
Next Earnings DateN/A
OptionableNot Optionable

Receive BCT News and Ratings via Email

Sign-up to receive the latest news and ratings for BCT and its competitors with MarketBeat's FREE daily newsletter.

Bluechiip (ASX:BCT) Frequently Asked Questions

How has Bluechiip's stock been impacted by COVID-19 (Coronavirus)?

Bluechiip's stock was trading at A$0.08 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BCT shares have decreased by 16.9% and is now trading at A$0.07. View which stocks have been most impacted by Coronavirus.

Has Bluechiip been receiving favorable news coverage?

News coverage about BCT stock has trended somewhat negative this week, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Bluechiip earned a daily sentiment score of -1.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutBluechiip.

Who are some of Bluechiip's key competitors?

Who are Bluechiip's key executives?

Bluechiip's management team includes the following people:
  • Mr. Andrew McLellan MBA, B Eng (Hons), GAICD, MD, CEO & Exec. Director
  • Mr. Lee D. Mitchell BA, LLM (Melb), Company Sec.

What is Bluechiip's stock symbol?

Bluechiip trades on the ASX under the ticker symbol "BCT."

What is Bluechiip's stock price today?

One share of BCT stock can currently be purchased for approximately A$0.07.

How big of a company is Bluechiip?

Bluechiip has a market capitalization of $40.92 million and generates $941,221.00 in revenue each year.

What is Bluechiip's official website?

The official website for Bluechiip is www.bluechiip.com.

How can I contact Bluechiip?

The company can be reached via phone at 61 3 9763 9763.

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.